CT-868
A Study of CT-868 in Type 1 Diabetes Mellitus
Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 111
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| CT-868 Low Dose | n/r | n/r | n/r | n/r | n/r |
| CT-868 Medium Dose | n/r | n/r | n/r | n/r | n/r |
| CT-868 High Dose | n/r | n/r | n/r | n/r | n/r |
| CT-868 Placebo | 2 participants | 0 participants | 2 participants | n/r | 0 |
| Arm 2: CT-868 Titrated to 1.8 mg | 13 participants | 4 participants | 6 participants | n/r | 0 |
| Arm 3: CT-868 Titrated to 4.1 mg | 17 participants | 8 participants | 6 participants | n/r | 0 |
| Arm 4: CT-868 Titrated to 6.6 mg | 9 participants | 8 participants | 6 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.